Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea
Public ClinicalTrials.gov record NCT02289352. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Therapeutic Equivalence of Brimonidine Topical Gel, 0.33% (Watson Laboratories, Inc., USA) to Reference Product Mirvaso® (Brimonidine) Topical Gel, 0.33% (Galderma Laboratories, L.P., USA) in Patients With Moderate to Severe Facial Erythema Associated With Rosacea
Study identification
- NCT ID
- NCT02289352
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Actavis Inc.
- Industry
- Enrollment
- 462 participants
Conditions and interventions
Conditions
Interventions
- Brimonidine Drug
- placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2014
- Primary completion
- Nov 30, 2014
- Completion
- Nov 30, 2014
- Last update posted
- Jan 13, 2020
2014
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigator site 2 | Hot Springs | Arkansas | 71913 | — |
| Investigator site 16 | Long Beach | California | 90813 | — |
| Investigator site 5 | Miami | Florida | 33015 | — |
| Investigator site 7 | Miami | Florida | 33175 | — |
| Investigator site 8 | Miramar | Florida | 33027 | — |
| Investigator site 6 | Ormond Beach | Florida | 32174 | — |
| Investigator site 3 | Carmel | Indiana | 46032 | — |
| Investigator site 9 | Louisville | Kentucky | 40202 | — |
| Investigator site 14 | Fridley | Minnesota | 55432 | — |
| Investigator site 15 | Henderson | Nevada | 89052 | — |
| Investigator site 1 | Albuquerque | New Mexico | 87106 | — |
| Investigator site 10 | High Point | North Carolina | 27262 | — |
| Investigator site 11 | Beachwood | Ohio | 44122 | — |
| Investigator site 4 | Nashville | Tennessee | 37215 | — |
| Investigator site 13 | College Station | Texas | 77845 | — |
| Investigator site 12 | Houston | Texas | 77055 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02289352, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 13, 2020 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02289352 live on ClinicalTrials.gov.